The role of immune responses in
tumor development is a central issue for
tumor biology and immunology.
IL-17 is an important
cytokine for inflammatory and
autoimmune diseases. Although IL-17-producing cells are detected in
cancer patients and
tumor-bearing mice, the role of
IL-17 in
tumor development is controversial, and mechanisms remain to be fully elucidated. In the current study, we found that the development of
tumors was inhibited in IL-17R-deficient mice. A defect in
IFN-gammaR increased
tumor growth, whereas
tumor growth was inhibited in mice that were deficient in both IL-17R and
IFN-gammaR compared with wild-type animals. Further experiments showed that neutralization of
IL-17 by Abs inhibited
tumor growth in wild-type mice, whereas systemic administration of
IL-17 promoted
tumor growth. The IL-17R deficiency increased CD8 T cell infiltration, whereas it reduced the infiltration of myeloid-derived suppressor cells (MDSCs) in
tumors. In contrast, administration of
IL-17 inhibited CD8 T cell infiltration and increased MDSCs in
tumors. Further analysis indicated that
IL-17 was required for the development and
tumor-promoting activity of MDSCs in
tumor-bearing mice. These data demonstrate that IL-17-mediated responses promote
tumor development through the induction of
tumor-promoting microenvironments at
tumor sites. IL-17-mediated regulation of MDSCs is a primary mechanism for its
tumor-promoting effects. The study provides novel insights into the role of
IL-17 in
tumor development and has major implications for targeting
IL-17 in treatment of
tumors.